首页>
外文期刊>Precision Radiation Oncology
>Safety and efficacy of programmed cell death‐1 antibody SHR‐1210 combined with concurrent chemoradiotherapy to treat locally advanced esophageal squamous cell carcinoma: a study protocol for an exploratory single‐arm phase Ib trial
【24h】
Safety and efficacy of programmed cell death‐1 antibody SHR‐1210 combined with concurrent chemoradiotherapy to treat locally advanced esophageal squamous cell carcinoma: a study protocol for an exploratory single‐arm phase Ib trial
Objective Esophageal squamous cell carcinoma (ESCC) is the most common pathological pattern in China, with poor prognosis due to its early and frequent metastasis. Definitive concurrent chemoradiotherapy is the standard treatment for inoperable locally advanced ESCC. Studies have shown promising efficacy of immune‐checkpoint inhibitors in ESCC. This study explores the safety and efficacy of immunotherapy combined with definitive concurrent chemoradiotherapy for locally advanced ESCC.
展开▼